ASH Conference Coverage
Filter News By:
Featured News
View all
More News
(Yahoo! Finance) Dec 12, 2019 - Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, presented positive data on Monday at the 2019 ASH Annual Meeting....
(NCI) Dec 10, 209 - New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute...
(bluebird bio) Dec 9, 2019 - bluebird bio, Inc. and Bristol-Myers Squibb announced updated safety and efficacy results from the ongoing Phase 1 study (CRB-402) of bb21217, an investigational BCMA-targeted chimeric antigen receptor (CAR) T...
(BMS) Dec 10, 2019 - Bristol-Myers Squibb Company today announced clinical results from the QUAZAR AML-001 study, evaluating investigational agent CC-486 as maintenance therapy in a broad population of patients with front-line, newly...
(Amgen) Dec 10, 2019 - Amgen today announced additional results from the primary analysis of the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to...
(ASH) Dec 10, 2019 - Using an investigational oral form of azacitidine therapy, CC-486, significantly improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard...
(ASH) Dec 10, 2019 - The immunotherapy drug blinatumomab significantly improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy in a study presented today during the 61st...
(Morningstar/Dow Jones) Dec 10, 2019 - Bristol-Myers Squibb Co. presented survival and safety data from its study evaluating CC-486 as maintenance therapy in a broad population of patients with front-line, newly diagnosed acute myeloid...
(St. Jude Children’s) Dec 10, 2019 - Findings presented by a St. Jude Children’s Research Hospital investigator showcase the power and potential of combining genomic and transcriptomic data.
(ASH) Dec 10, 2019 - Adding daratumumab to carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma led to a significant survival benefit, according to a study presented today during the 61st American...
Expert Videos

OBR Tweets

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20 https://t.co/NerWJUf67S

Aug 25
At the ASCO20 Virtual Education Program, Nilanjan Ghosh, MD, PhD, a hematologist-oncologist at the @LevineCancer, p… https://t.co/o2s69MGfrW

Aug 25
At the #ASCO20 Virtual Education Program, Jaleh Fallah @Jaleh_Fallah, MD, a Hematology/Oncology Fellow at the Cleve… https://t.co/QDkyebDuvp

Aug 25
The financial toxicity that patients and oncology practices are potentially exposed to due to the high costs associ… https://t.co/QA8A13PAGT

Aug 25
At separate #AACR and #COA virtual meetings held in July, participants discussed the challenges of providing cancer… https://t.co/8fs8SKl65a